Brand: Elicio Therapeutics Inc.
Capitalization: $ 180 million
Description: A biotech company that develops immunotherapy for the treatment of cancer and other diseases.
IPO date: 2021.07.22
Shares: 3.1 mln.
Offer range: $ 12.00 – $ 14.00
Elicio Therapeutics is a biotech company developing a range of new immunotherapy drugs for the treatment of cancer and other diseases.
For therapy aimed at involving the immune system in the treatment of disease, it is very important to target activation to a unique site where the immune response is generated.
Amphiphile’s patented platform, or AMP, delivers immunotherapy drugs directly to the brain center of the immune system.